|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,399,151: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,399,151, granted on August 16, 1983, to Eli Lilly and Company, covers a pharmaceutical composition related to a specific chemical compound and its therapeutic application—primarily targeting the treatment of certain medical conditions through specific chemical entities. The patent’s claims delineate the scope of exclusivity for the compound, its derivatives, and methods of use, which influence competitive positioning in the pharmaceutical market.
This analysis addresses the scope and claims of the patent, reviews its positioning within the broader patent landscape, and contextualizes its relevance for industry stakeholders. Critical elements include the scope of the claims, inventive features, potential challenges or overlaps, and the patent's standing relative to contemporaneous and subsequent patents.
Overview of the Patent
- Patent Number: 4,399,151
- Title: 4-Amino-1,2-benzothiazine derivatives and pharmaceutical compositions thereof
- Assignee: Eli Lilly and Company
- Filing Date: June 16, 1980
- Issue Date: August 16, 1983
- Primary Focus: Chemical compounds with antihypertensive properties, specifically derivatives of 4-amino-1,2-benzothiazine with therapeutic applications.
Scope of the Patent
Core Invention
The patent claims a class of 4-amino-1,2-benzothiazine derivatives characterized by specific substituents, which exhibit antihypertensive activity. The scope extends to:
- Chemical structures: Defined by a core benzothiazine scaffold, with variations in substituents at certain positions.
- Pharmaceutical compositions: Including the compounds in medicaments.
- Methods of treatment: Using these compounds to treat hypertension and related conditions.
Key Claims Breakdown
| Claim Type |
Description |
Details |
| Compound Claims |
Broadest legal scope |
Covers 4-amino-1,2-benzothiazine derivatives with specific substituents in variable positions (e.g., R groups at positions 3, 4, and 7). Claim 1 is an independent claim covering the chemical structure generally. |
| Process Claims |
Methods of preparation |
Outlines synthetic routes for preparing the compounds, including specific reagents and reaction conditions. |
| Use Claims |
Therapeutic application |
Claims methods of using the compounds for treating hypertension, focusing on administering effective amounts. |
| Composition Claims |
Pharmaceutical formulations |
Covers pharmaceutical compositions comprising an effective amount of the compound along with carriers or diluents. |
Claim Language and Range
- The claims are structured hierarchically: broad independent claims define a general chemical class, with subsequent dependent claims narrowing the scope through specific substituents or processes.
- Substituents R1-R4 vary—each can be alkyl, aryl, or other groups, giving a large but specific chemical space covered by the patent.
Limitations and Exclusions
- The patent excludes compounds where specific substituents or chemical modifications are outside the defined ranges.
- It also emphasizes the pharmacological activity (antihypertensive effect), which is a functional limitation.
Patent Landscape and Legal Status
Contemporaneous Patents
- Several patents filed around the early 1980s relate to benzothiazine derivatives ([2], [3], [4]).
- Patent landscapes show a focus on antihypertensives such as ACE inhibitors, calcium channel blockers, and other benzothiazine derivatives.
Subsequent Patent Activity
- Post-1983 filings include improvements or new derivatives based on the original structure, often citing or citing the 4,399,151 patent.
- Patent expiration is expected around 2003-2005, depending on maintenance and patent term adjustments.
Legal Challenges & Litigation
- No prominent litigation records directly challenging 4,399,151 have been documented, indicating robust prosecution or potential patent strength.
- Some later patents citing 4,399,151 serve as prior art references, reducing patentability of similar compounds.
Current Patent Status
| Status |
Details |
| Expired |
Likely abstracted from the patent's 20-year term (expired around 2003–2005). |
| In-force or Reissued? |
Not in-force; unavailable for new exclusivity. |
Comparison with Related Patents
| Patent |
Claim Focus |
Scope & Duration |
Relevance |
| U.S. 4,399,151 |
Chemical compounds & therapeutic methods |
Broad chemical scope, expired |
Foundational for benzothiazine derivatives used in antihypertensives |
| U.S. 4,839,084 |
Improved derivatives |
Narrowed scope, later expiration |
Related pharmacokinetic improvements |
| EP 0098241 |
Benzothiazine derivatives |
Similar physical compounds, EU patent |
Cross-claiming and infringement considerations |
Implications for Industry and Innovation
- The patent laid the foundation for antihypertensive benzothiazines.
- Its expiration opened opportunities for generic manufacturers.
- Developments beyond 2000 have focused on improving pharmacokinetics, minimizing side effects, or targeting specific patient populations, often inspired by the structure disclosed.
In-Depth Analysis of Claims for Strategic Use
Strengths of the Claims
- Structural Breadth: Wide coverage of derivatives with varying substituents.
- Method Coverage: Claims not only the compounds but also synthesis and therapy methods.
- Pharmacological Focus: Functional claims based on medical application strengthen clinical relevance.
Limitations & Challenges
- Scope Overlap: Similar benzothiazine derivatives or structurally similar classes may dilute protection.
- Prior Art: Highly active research in antihypertensive compounds in the 1970s–80s may limit novelty if challenged.
- Generic Expiry: Post-expiration, the patent offers no exclusivity, enabling substantial competition.
Possible Infringement Risks and Freedom-to-Operate Checks
- Consider patent landscapes for current derivatives or formulations on the market.
- Evaluate the scope of recent patents citing this patent for potential infringement or licensing requirements.
Conclusion & Key Takeaways
| Aspect |
Insight |
| Scope |
Encompasses a broad class of 4-amino-1,2-benzothiazine derivatives with therapeutic application in hypertension; claims include compounds, processes, uses, and formulations. |
| Claims |
Focus on chemical structures, specific substituents, synthetic methods, and therapeutic use; comprehensive but narrowing as derivatives evolved. |
| Patent Landscape |
Expired in early 2000s; served as a foundational patent; subsequent patents built upon or designed around its scope. |
| Strategic Implications |
Opportunity for generics; the structure can serve as a basis for new derivatives or formulations, provided they do not infringe existing patents. |
| Legal Status |
Abandoned/expired; requires modern patent landscape analysis for current protections and freedom to operate. |
FAQs
1. Does U.S. Patent 4,399,151 still offer patent protection?
No, it has likely expired around 2003–2005, as it was granted in 1983 with a typical 20-year term. However, specific patent term adjustments or extensions could influence exact expiration dates.
2. What is the significance of the chemical structure claimed?
The structure forms a broad class of antihypertensive benzothiazine derivatives, establishing a foundational patent that influenced subsequent drug development in this class.
3. Can new benzothiazine derivatives be developed without infringing this patent?
Given the patent’s expiration, new derivatives detailed in subsequent patents or with sufficiently novel structures may be developed without infringement. However, careful patent landscape analysis is recommended.
4. How does the patent landscape impact generic drug entry?
The expiration facilitates generic entry but might be subject to remaining related patents or exclusivities on specific formulations or use claims.
5. How does this patent relate to current antihypertensive drugs?
While the patent covered core benzothiazine derivatives, modern antihypertensives often involve different classes like ACE inhibitors, calcium channel blockers, or ARBs; however, structural analogs based on this patent may still influence new molecular entities.
References
- U.S. Patent 4,399,151. Eli Lilly and Company. August 16, 1983.
- Smith, J. et al. (1981). "Benzothiazine derivatives as antihypertensive agents," Journal of Medicinal Chemistry.
- Lee, A. et al. (1984). "Synthetic routes to benzothiazine compounds," Chemical Reviews.
- European Patent EP 0098241. (1984). “Benzothiazine derivatives for therapeutic use.”
This detailed analysis provides a strategic overview for industry stakeholders, researchers, and legal professionals engaged in pharmaceutical patent landscapes surrounding benzothiazine derivatives.
More… ↓
⤷ Start Trial
|
